Revised breast implant settlement agreed
This article was originally published in Clinica
Executive Summary
Inamed's McGhan subsidiary and Union Carbide have joined Bristol-Myers Squibb, Baxter and 3M in the revised settlement for breast implant litigation (see Clinica No 675, p 5). The new offer, agreed last week, provides compensation from $10,000 to $250,000 for present and future claimants. The deal covers fewer than half the 440,000 women who joined the global settlement. Bristol-Myers Squibb estimates that about 50,000 women with current illnesses and 140,000 who have registered for future claims will be covered by the deal.